Pfizer and Bristol-Myers Squibb (BMS) recently raised questions with and sought further clarity from the US Food and Drug Administration (FDA) on a draft guidance related to the risk-based monitoring ...
The US Food and Drug Administration (FDA) on Tuesday issued final guidance meant to assist drug and medical device makers in developing risk-based monitoring strategies for clinical investigations ...
This post is sponsored by IMARC Research, Inc. Since the August 2011 release of the draft guidance document by the FDA on a risk-based approach to monitoring, there has been a lot of buzz in the ...
New offering improves the quality and predictability of clinical development while reducing overall trial costs by up to 25 percent RESEARCH TRIANGLE PARK, NC – Quintiles today announced the launch of ...
In this free webinar, gain insight into the key elements to reduce risk for clinical trials. Attendees will learn how Independent Review and Data Analytics in eCOA strengthen endpoint integrity and ...
The U.S. Food and Drug Administration (FDA) recently finalized its guidance, “A Risk-Based Approach to Monitoring of Clinical Investigations” (the “2023 RBM Guidance”) which follows up on the Agency’s ...
WASHINGTON--(BUSINESS WIRE)--This week, the Association of Clinical Research Organizations (ACRO)’s RBQM Working Group published a paper in DIA’s Therapeutic Innovation & Regulatory Science journal ...
Organizations are integrating previously disparate services to better align their offerings with the shift from fee-for-service to risk-based care through visionary, member-centric solutions. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results